TY - JOUR
T1 - In vitro correlates of benzodiazepine cerebrospinal fluid uptake, pharmacodynamic action and peripheral distribution
AU - Arendt, R. M.
AU - Greenblatt, D. J.
AU - DeJong, R. H.
AU - Bonin, J. D.
AU - Abernethy, D. R.
AU - Ehrenberg, B. L.
AU - Giles, H. G.
AU - Sellers, E. M.
AU - Shader, R. I.
N1 - Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 1983
Y1 - 1983
N2 - Factors influencing the rate and extent of benzodiazepine uptake into cerebrospinal fluid (CSF), peripheral tissue distribution and electroencephalographic (EEG) effects were evaluated in a model utilizing anesthetized male cats. A single (0.25-10 mg/kg) dose of the following eight benzodiazepines was administered i.v.: diazepam, desmethyldiazepam, midazolam, lorazepam, alprazolam, triazolam, flunitrazepam and clobazam. Multiple samples were simultaneously drawn from arterial blood and cisternal CSF over the next 4 hr and the EEG was continuously monitored. Concentrations of benzodiazepines in plasma and CSF samples were measured by electron-capture gas-liquid chromatography and plasma protein binding determined by equilibrium dialysis. Physicochemical properties of lipophilicity of each benzodiazepine were determined by measurement of the octanol/buffer partition ratio at physiologic pH and by the high-pressure liquid chromatographic (HPLC) retention on a reverse-phase C18 column at neutral pH. Disappearance of all benzodiazepines from plasma was consistent with a linear sum of two or three exponential terms. After correction for individual differences in protein binding, volume of distribution (V(d)) of unbound drug was highly correlated with HPLC retention (r = 0.91), but not significantly related to octanol/buffer partition coefficient. Diazepam and midazolam, having the longest HPLC retention also had the largest unbound V(d). All benzodiazepines rapidly entered CSF, with peak concentrations usually attained within 15 min of dosage. More lipophilic drugs tended to enter CSF most rapidly, but associations of entry rate and in vitro lipophilicity were not significant. After distribution equilibrium was attained, disappearance of benzodiazepines from both plasma and CSF occurred in parallel. Equilibrium CSF/total plasma concentration ratios of all drugs were much less than unity. This was explained by plasma binding because equilibrium ratios were highly correlated with free fraction (r = 0.93, regression line slope = 0.98). All benzodiazepines produced diffuse low-frequency (1-5 Hz) EEG activity of very rapid onset after the i.v. dose. Onset rate was not correlated with in vivo lipophilicity. However, the duration of slow-wave activity differed markedly among drugs, having a high negative correlation with log of HPLC retention (r = 0.77) and with log of in vivo unbound V(d) (r = 0.87). Thus, benzodiazepine distribution in vivo is determined largely by lipid solubility, which in turn is reflected best by retention on a reverse-phase HPLC system. The rate of CSF entry, as well as the rate of onset of EEG slow-wave effects, were rapid and not significantly related to lipophilicity, but duration of EEG effects were longest for the least lipophilic drugs having the smallest V(d).
AB - Factors influencing the rate and extent of benzodiazepine uptake into cerebrospinal fluid (CSF), peripheral tissue distribution and electroencephalographic (EEG) effects were evaluated in a model utilizing anesthetized male cats. A single (0.25-10 mg/kg) dose of the following eight benzodiazepines was administered i.v.: diazepam, desmethyldiazepam, midazolam, lorazepam, alprazolam, triazolam, flunitrazepam and clobazam. Multiple samples were simultaneously drawn from arterial blood and cisternal CSF over the next 4 hr and the EEG was continuously monitored. Concentrations of benzodiazepines in plasma and CSF samples were measured by electron-capture gas-liquid chromatography and plasma protein binding determined by equilibrium dialysis. Physicochemical properties of lipophilicity of each benzodiazepine were determined by measurement of the octanol/buffer partition ratio at physiologic pH and by the high-pressure liquid chromatographic (HPLC) retention on a reverse-phase C18 column at neutral pH. Disappearance of all benzodiazepines from plasma was consistent with a linear sum of two or three exponential terms. After correction for individual differences in protein binding, volume of distribution (V(d)) of unbound drug was highly correlated with HPLC retention (r = 0.91), but not significantly related to octanol/buffer partition coefficient. Diazepam and midazolam, having the longest HPLC retention also had the largest unbound V(d). All benzodiazepines rapidly entered CSF, with peak concentrations usually attained within 15 min of dosage. More lipophilic drugs tended to enter CSF most rapidly, but associations of entry rate and in vitro lipophilicity were not significant. After distribution equilibrium was attained, disappearance of benzodiazepines from both plasma and CSF occurred in parallel. Equilibrium CSF/total plasma concentration ratios of all drugs were much less than unity. This was explained by plasma binding because equilibrium ratios were highly correlated with free fraction (r = 0.93, regression line slope = 0.98). All benzodiazepines produced diffuse low-frequency (1-5 Hz) EEG activity of very rapid onset after the i.v. dose. Onset rate was not correlated with in vivo lipophilicity. However, the duration of slow-wave activity differed markedly among drugs, having a high negative correlation with log of HPLC retention (r = 0.77) and with log of in vivo unbound V(d) (r = 0.87). Thus, benzodiazepine distribution in vivo is determined largely by lipid solubility, which in turn is reflected best by retention on a reverse-phase HPLC system. The rate of CSF entry, as well as the rate of onset of EEG slow-wave effects, were rapid and not significantly related to lipophilicity, but duration of EEG effects were longest for the least lipophilic drugs having the smallest V(d).
UR - http://www.scopus.com/inward/record.url?scp=0021048956&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021048956&partnerID=8YFLogxK
M3 - Article
C2 - 6137558
AN - SCOPUS:0021048956
SN - 0022-3565
VL - 227
SP - 98
EP - 106
JO - Journal of Pharmacology and Experimental Therapeutics
JF - Journal of Pharmacology and Experimental Therapeutics
IS - 1
ER -